6/12
07:22 am
rgnx
REGENXBIO names new chief executive [Seeking Alpha]
Medium
Report
REGENXBIO names new chief executive [Seeking Alpha]
6/12
07:12 am
rgnx
REGENXBIO Announces Leadership Transition [Yahoo! Finance]
Low
Report
REGENXBIO Announces Leadership Transition [Yahoo! Finance]
6/12
07:05 am
rgnx
REGENXBIO Announces Leadership Transition
Low
Report
REGENXBIO Announces Leadership Transition
6/11
12:14 am
rgnx
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy [Seeking Alpha]
Low
Report
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy [Seeking Alpha]
6/10
10:07 pm
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
6/7
08:05 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $38.00 price target on the stock.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $38.00 price target on the stock.
6/5
07:05 am
rgnx
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Low
Report
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
5/30
10:02 pm
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
5/25
09:15 am
rgnx
It Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The Microscope [Yahoo! Finance]
Medium
Report
It Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The Microscope [Yahoo! Finance]
5/15
12:25 pm
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its price target raised by analysts at HC Wainwright from $36.00 to $38.00. They now have a "buy" rating on the stock.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its price target raised by analysts at HC Wainwright from $36.00 to $38.00. They now have a "buy" rating on the stock.
5/11
08:49 am
rgnx
Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results [Yahoo! Finance]
Low
Report
Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results [Yahoo! Finance]
5/10
07:11 am
rgnx
REGENXBIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
REGENXBIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]
5/10
07:05 am
rgnx
REGENXBIO to Participate in Upcoming Investor Conferences
Medium
Report
REGENXBIO to Participate in Upcoming Investor Conferences
5/9
04:00 pm
rgnx
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/8
07:34 pm
rgnx
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]
Medium
Report
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]
5/8
04:12 pm
rgnx
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights [Yahoo! Finance]
Medium
Report
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights [Yahoo! Finance]
5/8
04:05 pm
rgnx
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Medium
Report
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
5/8
12:34 am
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
REGENXBIO Inc. (NASDAQ: RGNX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
5/1
02:22 pm
rgnx
Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market [Yahoo! Finance]
Low
Report
Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market [Yahoo! Finance]
5/1
07:25 am
rgnx
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights [Yahoo! Finance]
Medium
Report
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights [Yahoo! Finance]
5/1
07:05 am
rgnx
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
Medium
Report
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
4/29
06:09 am
rgnx
Coave Therapeutics Showcases its ALIGATER™ Platform for Generating Conjugated AAV (coAAV) Vectors Exhibiting Superior Performance in Delivering Ocular Gene Therapy through the Suprachoroidal Route [Yahoo! Finance]
Low
Report
Coave Therapeutics Showcases its ALIGATER™ Platform for Generating Conjugated AAV (coAAV) Vectors Exhibiting Superior Performance in Delivering Ocular Gene Therapy through the Suprachoroidal Route [Yahoo! Finance]
4/24
07:05 am
rgnx
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Low
Report
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
4/17
07:29 am
rgnx
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures [Yahoo! Finance]
Low
Report
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures [Yahoo! Finance]
4/12
12:11 pm
rgnx
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $40.00 price target on the stock.
Medium
Report
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $40.00 price target on the stock.